InMode (INMD) Net Income towards Common Stockholders (2018 - 2026)
InMode (INMD) posted quarterly Net Income towards Common Stockholders of $11.6 million for Q1 2026, down 36.48% year-on-year from $18.2 million in Q1 2025, and down 67.49% on a QoQ basis from $35.6 million in Q4 2025.
InMode (INMD) Net Income towards Common Stockholders (2018 - 2026) Analysis & Trends
InMode (INMD) has reported Net Income towards Common Stockholders for 9 consecutive years, with $11.6 million the latest figure, recorded in Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 36.48% year-over-year to $11.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $95.7 million (up 28.22% YoY) and the FY2025 annual result came in at $126.8 million, up 20.03% from the prior year.
- Net Income towards Common Stockholders declined to $11.6 million in Q1 2026 per INMD's latest filing, from $35.6 million in the prior quarter.
- Over the last five years, Net Income towards Common Stockholders for INMD reached as high as $65.2 million in Q4 2023 and fell as low as -$18.4 million in Q4 2024.
- A 5-year average of $33.1 million and a median of $35.6 million in 2025 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders sank 128.16% — and 2025, when it soared 293.77%.
- Year by year, Net Income towards Common Stockholders stood at $37.7 million in 2022, then jumped by 72.81% to $65.2 million in 2023, then sank by 128.16% to -$18.4 million in 2024, then surged by 293.77% to $35.6 million in 2025, then sank by 67.49% to $11.6 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered $11.6 million, $35.6 million, and $21.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.58 Bn | 176.28 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 129.01 Bn | 126.13 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 108.52 Bn | 99.30 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 68.67 Bn | 67.22 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 48.33 Bn | 44.66 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.34 Bn | 27.23 Bn | 750.30 Mn | 199.50 Mn |
| 7 | GE HealthCare Technologies | 28.07 Bn | 25.79 Bn | 1.98 Bn | 411.00 Mn |
| 8 | Smith & Nephew | 26.89 Bn | 26.31 Bn | - | - |
| 9 | Koninklijke Philips | 24.12 Bn | 21.00 Bn | 2.07 Bn | 176.78 Mn |
| 10 | InMode | 978,277.45 | -479.15 Mn | 61.55 Mn | 11.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.56 Mn |
| Dec 31, 2025 | 35.56 Mn |
| Sep 30, 2025 | 21.86 Mn |
| Jun 30, 2025 | 26.74 Mn |
| Mar 31, 2025 | 18.20 Mn |
| Dec 31, 2024 | -18.35 Mn |
| Sep 30, 2024 | 50.99 Mn |
| Jun 30, 2024 | 23.82 Mn |
| Mar 31, 2024 | 23.70 Mn |
| Dec 31, 2023 | 65.16 Mn |
| Sep 30, 2023 | 46.52 Mn |
| Jun 30, 2023 | 55.73 Mn |
| Mar 31, 2023 | 40.51 Mn |
| Dec 31, 2022 | 37.71 Mn |
| Sep 30, 2022 | 48.79 Mn |
| Jun 30, 2022 | 44.05 Mn |
| Mar 31, 2022 | 30.98 Mn |
| Dec 31, 2021 | 52.69 Mn |
| Sep 30, 2021 | 44.72 Mn |
| Jun 30, 2021 | 40.93 Mn |